Last updated: May 30, 2026
Levetiracetam in Sodium Chloride Suppliers: Who Manufactures IV Levetiracetam Saline and What’s the Supply Chain Footprint?
Levetiracetam in sodium chloride is an intravenous (IV) dosage form that typically uses a sterile, premixed solution for infusion. Suppliers fall into two buckets: (1) original manufacturers of the premixed product and (2) contract manufacturing organizations (CMOs) that produce sterile IV liquids and package them into final containers (bag/vial) for brand and label owners.
No actionable supplier roster can be produced from the information provided. The term “levetiracetam in sodium chloride” maps to multiple strengths, container types, label holders, and regulatory listings that materially change supplier identity. Without product-specific identifiers (strength, container, NDA/ANDA or NDC, FDA submission), any named “supplier” list would be unreliable.
What counts as a “supplier” for IV levetiracetam in sodium chloride?
Featured search intent typically splits into these procurement categories:
- Label holder / marketing authorization holder (owns the FDA approval and is the source of record for sales in the US).
- Drug substance and sterile DP manufacturer (API site versus sterile fill-finish site).
- Packaging and container supplier (bag/vial, stoppers, seals, overwraps).
- CMO / sterile contractor (fills, sterilizes, and packages final sterile liquid).
- Distributor (wholesaler network, not a manufacturer, but often what hospitals buy through).
Which product attributes determine the actual IV levetiracetam saline supplier?
For IV premixed drugs, the supplier chain changes based on:
- Strength (for example, mg/mL concentration).
- Container (typically IV infusion bag versus vial).
- Fill volume (common volumes differ by NDC and package configuration).
- Regulatory listing (NDA versus ANDA versus repack label).
- Sterile process (aseptic fill versus terminal sterilization where applicable).
- Hold and transport specs (temperature control, light protection, shelf-life).
How can you identify suppliers for levetiracetam in sodium chloride in the US market?
Answer: supplier identity in the US should be tied to FDA product listing (Orange Book if applicable), NDC structure, and label configuration.
- Use the NDC to match the product strength and package to the labeler/holder and to determine the manufacturing site(s) used on the label.
- Use the FDA listing to confirm the approved presentation and label holder.
- If investigating CMOs, match the site(s) shown for the finished product to corporate sterile fill-finish capabilities in regulatory records.
Which patents and FDA status control how many suppliers can enter?
Answer: IV premix products are typically constrained by:
- Drug product approvals (NDA/ANDA) tied to the formulation and manufacturing process.
- Data exclusivity (where relevant) and any listed patents in the FDA systems for reference products.
- Sterile manufacturing capacity (limited number of CMOs can produce sterile IV liquids at scale to the required quality system).
What generic entry risks exist for IV levetiracetam saline?
Answer: generic entry risk is driven by:
- Whether the reference product’s sterile liquid, container, and strength create practical and regulatory hurdles.
- Whether potential challengers can satisfy bioequivalence and product-specific chemistry, manufacturing, and controls.
- Capacity and compliance performance at sterile fill-finish sites.
How many suppliers typically exist for IV premixed levetiracetam?
Answer: market supply count varies by:
- Geography and contracting cycles (US hospital purchasing is often fragmented by GPO contracts).
- Shortages and seasonal distribution.
- Labeler consolidation where one CMO supplies multiple labelers.
What are common sterile CMO capabilities required for levetiracetam sodium chloride IV?
Sterile IV liquid suppliers generally need:
- Sterile fill-finish for aqueous solutions.
- Container compatibility (bag/vial material selection compatible with the solution and any stabilizers).
- Validation for the specific container and fill volume.
- Sterility assurance controls (environmental monitoring, aseptic process controls).
- Stability program aligned to storage and expiration.
What procurement channels do hospitals use for levetiracetam in sodium chloride?
Answer: hospitals typically procure through:
- GPO-negotiated distributors (availability depends on labeler and inventory allocations).
- Direct contracts with manufacturers or their authorized distributors.
- Emergency supply channels during shortage events.
Key Takeaways
- “Levetiracetam in sodium chloride” is a product-description class, not a unique identifier. Supplier identity depends on strength, container, and FDA/label configuration.
- A reliable supplier list must be anchored to NDC and labeler/holder (and, for manufacturing inquiries, the finished dose site shown on the label).
- Sterile IV manufacturing and packaging constraints largely determine how many qualified suppliers can serve the market.
FAQs
- What’s the difference between levetiracetam IV premix and levetiracetam injections prepared from powder?
- How do NDCs map to the label holder and finished-product manufacturer for IV sterile liquids?
- Which sterile fill-finish process (aseptic vs terminal sterilization) is used for IV levetiracetam saline?
- Do shortage events change the supplier list for levetiracetam in sodium chloride at hospital level?
- How do container type and strength affect generic and CMO sourcing for IV levetiracetam?
References
No sources are cited because no product-specific FDA listing, NDC, or regulatory identifiers were provided.
